Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill data on file, last reported at $44.0 million in Q1 2026.

• Goodwill for Q1 2026 came in at $44.0 million, down 0.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.0 million (down 0.91% YoY), and the FY2025 annual result was $44.0 million, changed 0.0% from the prior year.
• Goodwill steadied at $44.0 million in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Over five years, Goodwill peaked at $44.4 million in Q1 2022 and troughed at $44.0 million in Q4 2024.
• A 5-year average of $44.3 million and a median of $44.4 million in 2022 frame the typical range for Goodwill.
• The sharpest annual moves came in 2022 and 2024: Goodwill changed 0.0% in 2022, then declined 0.91% in 2024.
• A 5-year view of Goodwill shows it stood at $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then declined by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025, then changed by 0.0% to $44.0 million in 2026.
• Business Quant data shows RARE's Goodwill at $44.0 million in Q1 2026, $44.0 million in Q4 2025, and $44.4 million in Q3 2025.